Genome editing (GE) is a promising strategy for gene therapy. Engineered nucleases such as TALE and CRISPR-Cas9 can now be used to target a double strand break (DSB) at any DNA sequence of interest in the genome in order to stimulate GE. For gene therapy and several important applications, it is important to favour DSB repair by homologous recombination in order to perform highly controlled and precise GE. The program partners have longstanding experience in programmable nucleases, studies of DSB repair and gene therapy approaches. Partner 2 has proposed a two step model of DSB repair pathway choice. The research programme consists in taking advantage of current knowledge of DSB repair pathways to test original strategies for increasing the efficiency of GE by HR. A second task will consist in identifying new positive regulators to stimulate HR. Importantly, the most promising strategies will be tested, including one strategy already validated in the experimental systems used by Partners 1 & 2, and optimized in 2 different models of human genetic disease in which better, more efficacious therapeutic options are needed.
Monsieur jean-paul concordet (INSERM U1154)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
INSERM INSERM U1154
RReC ReCC UMR8200 CNRS
UMR_S 951 INTEGRARE Integrated genetic approaches in therapeutic discovery for rare diseases
Help of the ANR 652,320 euros
Beginning and duration of the scientific project: November 2016 - 48 Months